Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan

Taichi Isobe, Keita Uchino, Chinatsu Makiyama, hiroshi ariyama, Shuji Arita, Shingo Tamura, Masato Komoda, Hitoshi Kusaba, Tsuyoshi Shirakawa, Taito Esaki, Kenji Mitsugi, Shigeo Takaishi, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

8 引用 (Scopus)

抄録

Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified. Patients and Methods: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed. Results: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385). Conclusion: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.

元の言語英語
ページ(範囲)2035-2040
ページ数6
ジャーナルAnticancer Research
34
発行部数4
出版物ステータス出版済み - 1 1 2014

Fingerprint

Colorectal Neoplasms
Japan
Drug Therapy
Hypertension
Prehypertension
Hemorrhage
Thromboembolism
Residual Neoplasm
Bevacizumab
Proteinuria
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. / Isobe, Taichi; Uchino, Keita; Makiyama, Chinatsu; ariyama, hiroshi; Arita, Shuji; Tamura, Shingo; Komoda, Masato; Kusaba, Hitoshi; Shirakawa, Tsuyoshi; Esaki, Taito; Mitsugi, Kenji; Takaishi, Shigeo; Akashi, Koichi; Baba, Eishi.

:: Anticancer Research, 巻 34, 番号 4, 01.01.2014, p. 2035-2040.

研究成果: ジャーナルへの寄稿記事

Isobe, T, Uchino, K, Makiyama, C, ariyama, H, Arita, S, Tamura, S, Komoda, M, Kusaba, H, Shirakawa, T, Esaki, T, Mitsugi, K, Takaishi, S, Akashi, K & Baba, E 2014, 'Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan', Anticancer Research, 巻. 34, 番号 4, pp. 2035-2040.
Isobe, Taichi ; Uchino, Keita ; Makiyama, Chinatsu ; ariyama, hiroshi ; Arita, Shuji ; Tamura, Shingo ; Komoda, Masato ; Kusaba, Hitoshi ; Shirakawa, Tsuyoshi ; Esaki, Taito ; Mitsugi, Kenji ; Takaishi, Shigeo ; Akashi, Koichi ; Baba, Eishi. / Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan. :: Anticancer Research. 2014 ; 巻 34, 番号 4. pp. 2035-2040.
@article{8a704e634a3846ad982c4d3068ba58db,
title = "Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan",
abstract = "Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified. Patients and Methods: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed. Results: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22{\%}, 2{\%}, 7{\%}, 16{\%}, and 8{\%} of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7{\%}) and 6 out of 63 patients with no primary tumor (8.7{\%}) (p=0.385). Conclusion: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.",
author = "Taichi Isobe and Keita Uchino and Chinatsu Makiyama and hiroshi ariyama and Shuji Arita and Shingo Tamura and Masato Komoda and Hitoshi Kusaba and Tsuyoshi Shirakawa and Taito Esaki and Kenji Mitsugi and Shigeo Takaishi and Koichi Akashi and Eishi Baba",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "34",
pages = "2035--2040",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

TY - JOUR

T1 - Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan

AU - Isobe, Taichi

AU - Uchino, Keita

AU - Makiyama, Chinatsu

AU - ariyama, hiroshi

AU - Arita, Shuji

AU - Tamura, Shingo

AU - Komoda, Masato

AU - Kusaba, Hitoshi

AU - Shirakawa, Tsuyoshi

AU - Esaki, Taito

AU - Mitsugi, Kenji

AU - Takaishi, Shigeo

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified. Patients and Methods: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed. Results: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385). Conclusion: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.

AB - Background: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified. Patients and Methods: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed. Results: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385). Conclusion: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.

UR - http://www.scopus.com/inward/record.url?scp=84902283314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902283314&partnerID=8YFLogxK

M3 - Article

VL - 34

SP - 2035

EP - 2040

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4

ER -